Literature DB >> 31935161

Inferior Meatus Augmentation Procedure (IMAP) to Treat Empty Nose Syndrome: A Pilot Study.

Andrew Thamboo1,2, Sachi S Dholakia2, Nicole A Borchard2, Vishal S Patel3, Navarat Tangbumrungtham4, Nathalia Velasquez5, Zhenxiao Huang6, David Zarabanda2, Tsuguhisa Nakayama7, Jayakar V Nayak2.   

Abstract

Our understanding of empty nose syndrome (ENS) continues to evolve. Prior studies evaluating airway augmentation to treat ENS did not use validated disease-specific questionnaires, making the true impact of these surgeries unclear. We present a case series of 10 patients with ENS (11 procedures) who underwent the inferior meatus augmentation procedure (IMAP) between September 2014 and May 2017. Subjective outcomes of IMAP included comparisons of preoperative and postoperative assessments (1 week, 1 month, 3 months, 6 months) using the Empty Nose Syndrome 6-item Questionnaire (ENS6Q), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder 7-item Scale (GAD-7), and Sino-Nasal Outcome Test-22 (SNOT-22). The decrement in ENS6Q scores observed maintained statistical significance at 6 months (P ≤ .001). Similar results were achieved with PHQ-9, GAD-7, and SNOT-22 (P ≤ .01, P ≤ .01, P ≤ .001, respectively). IMAP can dramatically improve the quality of life of ENS patients regarding both ENS-specific symptoms and psychological well-being.

Entities:  

Keywords:  SNOT-22; alloderm; atrophic rhinitis; empty nose syndrome; implant; inferior meatus augmentation; psychiatric disorder; small intestinal submucosa; turbinoplasty; upper airway

Year:  2020        PMID: 31935161     DOI: 10.1177/0194599819900263

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  1 in total

1.  Inferior meatus augmentation procedure (IMAP) normalizes nasal airflow patterns in empty nose syndrome patients via computational fluid dynamics (CFD) modeling.

Authors:  Jennifer Malik; Sachi Dholakia; Barak M Spector; Angela Yang; Dayoung Kim; Nicole A Borchard; Andrew Thamboo; Kai Zhao; Jayakar V Nayak
Journal:  Int Forum Allergy Rhinol       Date:  2020-11-29       Impact factor: 3.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.